Krystal Biotech Appoints Catherine Mazzacco to Board of Directors
March 06 2023 - 7:00AM
Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) a
biotechnology company focused on developing and commercializing
genetic medicines for patients with rare diseases, today announced
the appointment of Catherine Mazzacco to its Board of Directors.
“I am pleased to welcome Catherine to our Board of Directors at
this crucial next stage of Krystal’s evolution,” said Krish S.
Krishnan, Chairman and Chief Executive Officer of Krystal Biotech,
Inc. “As a seasoned executive with extensive valuable
pharmaceutical and biotechnology industry experience, I look
forward to Catherine’s involvement and assistance in guiding our
strategic objectives.”
“After watching the strong execution of Krystal over the past
years, I am excited to join the Company’s Board of Directors at
this pivotal stage for the Company,” said Ms. Mazzacco. “I look
forward to working with the other board members and the leadership
team to continue Krystal’s commercialization preparedness while
advancing the rest of the pipeline and transform lives with
treatments in genetic rare diseases.”
Ms. Mazzacco was Chief Executive Officer and President of LEO
Pharma, a privately owned global pharmaceutical company. Prior to
this role, Ms. Mazzacco was Senior Vice President, Global
Commercial Operations, Life Sciences Division at GE HealthCare.
Before joining GE HealthCare, Ms. Mazzacco spent over 25 years at
Abbott Laboratories (NYSE: ABT) holding global senior operational
and strategic leadership roles, including, most recently, Vice
President, Global Commercial Operations, Abbott Vision Division.
Ms. Mazzacco is a Member of the Supervisory Board and Remuneration
& Nomination Committee of Servier, a privately owned global
pharmaceutical company. Ms. Mazzacco holds a BSE, Engineering,
Option Biotechnology from the University of Compiègne in
France.
About Krystal Biotech, Inc.
Krystal Biotech, Inc. (NASDAQ: KRYS) is a biotechnology company
focused on developing and commercializing genetic medicines for
patients with rare diseases. The Company’s wide-ranging pipeline is
based on its proprietary redosable HSV vector. Headquartered in
Pittsburgh, Pennsylvania, the Company is led by an experienced
management team, is fully-integrated and has core capabilities in
viral vector design, vector optimization, gene therapy
manufacturing and commercialization. For more information, please
visit http://www.krystalbio.com, and follow @KrystalBiotech on
LinkedIn and Twitter.
CONTACT:
Investors and Media
Meg Dodge
Krystal Biotech
mdodge@krystalbio.com
Krystal Biotech (NASDAQ:KRYS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Krystal Biotech (NASDAQ:KRYS)
Historical Stock Chart
From Jul 2023 to Jul 2024